Copyright
©The Author(s) 2016.
World J Clin Pediatr. Feb 8, 2016; 5(1): 47-56
Published online Feb 8, 2016. doi: 10.5409/wjcp.v5.i1.47
Published online Feb 8, 2016. doi: 10.5409/wjcp.v5.i1.47
Ref. | Year | Age | No. of patients | Product | Efficacy parameters | Duration | Statisticalsignificance | Other observation |
Wüthrich et al[13] | 2003 | 4-11 | 22 | ALK-Abello’ | Medication score | 2 yr | P = 0.05 | A difference in drug consumption has been shown only in the second year |
Bufe et al[14] | 2004 | 6-12 | 161 | Sublivac BEST, HAL-allergy | Clinical Index (combining | 3 yr | P = 0.046 | A significant difference was shown in patients with severe symptoms |
symptom and medication score) | ||||||||
Rolinck-Werninghaus[15] | 2004 | 3-14 | 97 | Pangramin-SLIT | Multiple symptom – medication score | 32 mo | P = 0.498 | Symptom score did not reveal significant difference; medication score improve significantly (P = 0.0025) |
ALK-SCHERAX | ||||||||
Novembre et al[16] | 2004 | 5-14 | 113 | ALK-Abello’ | Medication score | 3 yr | P < 0.05 | Significant improvement was shown after the second year; symptom score did not improve significantly |
Röder et al[17] | 2007 | 6-18 | 204 | Oralgen Grass Pollen, Artu Biologicals | Medication and symptom score | 2 yr | NS | Study population was enrolled from general practices |
Wahn et al[18] | 2009 | 5-17 | 278 | 5-grass tablets 300IR, | Rhinoconjunctivitis total symptom score | 6 mo | P = 0.001 | SLIT was started 4 mo before before the pollen season; both symptom score and medication score improved singularly too |
Bufe et al[19] | 2009 | 5-16 | 253 | Stallergenes | Medication and symptom score | 4-6 mo | P < 0.02 | SLIT was started 8 to 23 wk before the estimated pollen season in 2007 |
SQ-standardized grass allergen tablet (Grazax) | ||||||||
Halken et al[20] | 2010 | 5-17 | 267 | 5-grass tablets 300IR, | Medication and symptom score | 6 mo | P < 0.01 | SLIT was started 4 mo before the estimated pollen season |
Stelmach et al[29] | 2011 | 6-18 | 60 | Stallergenes Staloral 300IR, Stallergenes | Combined symptom and medication score | 2 yr | P < 0.01 | Both pre-coseasonal and continuous regimen were efficacious in the same extent |
Blaiss et al[21] | 2011 | 5-17 | 345 | SQ-standardized grass allergen tablet (Grazax) | Medication and symptom score | 6 mo | P < 0.01 | SLIT started 8 wk before the pollen 2009 season; 89% patients were multi-sensitized |
Wahn et al[23] | 2012 | 4-12 | 207 | 6-grass pollen aqueous extract (AllerSlit, Allergopharma) | Area under the curve of symptom-medication score | 6-8 mo | P = 0.004 | Patients were treated with a pre-coseasonal regimen; after this first phase, unblinding was made and all patients were treated |
Ahmadiafshar et al[22] | 2012 | 5-18 | 24 | Staloral 300IR, Stallergenes | Medication and symptom score | 6 mo | P < 0.05 | SLIT was started 8-10 wk before pollen season |
- Citation: Poddighe D, Licari A, Caimmi S, Marseglia GL. Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence. World J Clin Pediatr 2016; 5(1): 47-56
- URL: https://www.wjgnet.com/2219-2808/full/v5/i1/47.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v5.i1.47